Volume 43, Issue 2 (7-2019)
Research in Medicine 2019, 43(2): 105-117 |
Back to browse issues page
Rooyan research centre , hoda.madani@royaninstitute.org
Abstract: (5908 Views)
Background: In spite of promising results of conventional treatments for myocardial infarction, including
medications, stent implantation, and coronary artery bypass grafting, the disease and its complications,
especially heart failure, are highly prevalent because these methods could not reverse the cell loss, which
is the main problem. Currently, heart transplantation, as the last option for treatment of heart failure, has
major limitations including the low number of appropriate donors and underlying diseases in recipients.
Materials and Methods: The present study is presented as a review paper. Using related keywords, including
myocardial infarction, cell therapy, stem cell, cardiac tissue engineering, and clinical trials, studies published
up to 2018 were collected from reliable databases, including Google Scholar, PubMed, Scopus, and Elsevier.
Among potential candidates, those which were the most relevant to the purposes of the study were selected
and evaluated.
Results: The stem cells application for regeneration of damaged tissues is one of the great researchers’
achievements. In spite of various scientific, legal, and ethical concerns, several companies target stem cells
transplantation for cardiac diseases in commercial way. There are many in situ, in vitro, and cell-loaded
scaffold and cell sheet engineering studies in tissue engineering field.
Conclusion: Despite the promising results of stem cells application, many challenges still lay ahead of this
pathway including optimal cell, dosage, time and route administration selection, and the immune response
modulations. Currently, extensive research is ongoing. In this regard, the successful results of various clinical
trials made by different companies and health centers have led to commercialization of products. Some of
them are addressed in the current review article. However, more research is needed to clarify the efficacy of
these studies.
medications, stent implantation, and coronary artery bypass grafting, the disease and its complications,
especially heart failure, are highly prevalent because these methods could not reverse the cell loss, which
is the main problem. Currently, heart transplantation, as the last option for treatment of heart failure, has
major limitations including the low number of appropriate donors and underlying diseases in recipients.
Materials and Methods: The present study is presented as a review paper. Using related keywords, including
myocardial infarction, cell therapy, stem cell, cardiac tissue engineering, and clinical trials, studies published
up to 2018 were collected from reliable databases, including Google Scholar, PubMed, Scopus, and Elsevier.
Among potential candidates, those which were the most relevant to the purposes of the study were selected
and evaluated.
Results: The stem cells application for regeneration of damaged tissues is one of the great researchers’
achievements. In spite of various scientific, legal, and ethical concerns, several companies target stem cells
transplantation for cardiac diseases in commercial way. There are many in situ, in vitro, and cell-loaded
scaffold and cell sheet engineering studies in tissue engineering field.
Conclusion: Despite the promising results of stem cells application, many challenges still lay ahead of this
pathway including optimal cell, dosage, time and route administration selection, and the immune response
modulations. Currently, extensive research is ongoing. In this regard, the successful results of various clinical
trials made by different companies and health centers have led to commercialization of products. Some of
them are addressed in the current review article. However, more research is needed to clarify the efficacy of
these studies.
Keywords: Myocardial Infarction, Cell Therapy, Stem Cell, Cardiac Tissue Engineering, Scaffold, Clinical Trials
Type of Study: Original |
Subject:
Cellular Sciences (Molecular Cells, Stem Cells)
Received: 2019/03/18 | Accepted: 2019/03/18 | Published: 2019/07/16
Received: 2019/03/18 | Accepted: 2019/03/18 | Published: 2019/07/16
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |